Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
École Nationale Supérieure De Chimie De Montpellier is managing 2 pending office actions in the Biotechnology & Pharmaceuticals area. These actions involve 2 distinct examiners but are concentrated within 1 distinct art unit. HIRAKIS, SOPHIA P is the busiest examiner with 1 pending action.
While multiple examiners are involved, the use of a single distinct art unit suggests a consistent administrative environment for the pending matters. This allows for a unified approach to the technical standards of that specific unit. Practitioners can benefit from this centralization by applying successful arguments from the pending matters across the entire portfolio. The presence of 2 distinct examiners ensures that each case receives individual review.
The Biotechnology & Pharmaceuticals sector often requires precise claim language and consistent technical descriptions. By focusing the prosecution within 1 distinct art unit, the applicant can minimize the risk of conflicting interpretations. The current distribution of work across the assigned examiners ensures that each matter receives individual attention while remaining within the same technical group, facilitating a more efficient path toward allowance for both pending actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 1 | 56.1% | +73.5% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562251 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | HIRAKIS, SOPHIA P | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562251 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | HIRAKIS, SOPHIA P | 34d |
| 18254315 | COMPOUNDS FOR TREATING SEGMENTAL PROGEROID SYNDROMES | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562251 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | HIRAKIS, SOPHIA P | 1623 | §103§112 | Final Rejection | 34d | Pending | Nov 17, 2023 |
| 18254315 | COMPOUNDS FOR TREATING SEGMENTAL PROGEROID SYNDROMES | CHONG, YONG SOO | 1623 | §102 | Non-Final OA | — | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial